Hikma Pharmaceuticals Plc Additional Listing (9885V)
January 21 2013 - 5:17AM
UK Regulatory
TIDMHIK
RNS Number : 9885V
Hikma Pharmaceuticals Plc
21 January 2013
Block Listing of Shares
Hikma Pharmaceuticals PLC
LONDON, 21 January 2013 - The Board of Hikma Pharmaceuticals PLC
("Hikma") (LSE: HIK) (NASDAQ: HIK), announces that it has made a
block listing application to the Financial Services Authority and
the London Stock Exchange plc for a total of 1,000,000 ordinary
shares of 10p each in the capital of the Company to be admitted to
the Official List of the UK Listing Authority. It is expected that
admission will be granted on 24 January 2013.
The shares, when issued, will be issued fully paid and rank pari
passu in all respects with the existing issued ordinary shares of
the Company. The shares will be issued pursuant to the vesting of
shares under the Hikma Pharmaceuticals PLC 2005 Long Term Incentive
Plan (the "Plan"). Participants in the Plan have or will become
entitled to these shares following the vesting of the shares.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non--branded generic
and in--licensed products. Hikma's operations are conducted through
three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader, the United States and Europe. In 2011,
Hikma achieved revenue of $918.0 million and profit attributable to
shareholders of $80.1 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISPGUQGGUPWGUG
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024